In this episode, Maya meets Gretchen Knoll. She has over 20 years of experience in pharmaceutical clinical development, now she focuses on enhancing care for severely ill patients and reducing healthcare costs through strategic collaborations.  Maya and Gretchen Knoll discuss the challenges and potential transformations in clinical research. They delve into the need for a shift from organ-based cancer treatment to tumor classification, the importance of patient empowerment and education, and the potential of AI and predictive analytics in advancing drug discovery and personalized medicine. (00:54) Getting to know Gret Knoll (02:49) Why do we need to shift from organ to receptor-based classification (07:29) The challenges with using molecular testing at scale (15:09) What are the challenges and opportunities in clinical trials (21:20) What is the new role of psychedelics in clinical research (30:17) The power of predictive analytics and AI in medicine (32:40) How to empower patients for better trial outcomes Mentioned in this episode: Fabrice André: Gretchen references an article by Fabrice André in Nature magazine, discussing his frustrations with current cancer treatment methodologies. "Forget lung, breast or prostate cancer: why tumour naming needs to change” FindMeCure: Maya mentions FindMeCure, a platform that supports patients in finding clinical trials.Gustave Roussy Institute: Gretchen notes the Gustave Roussy Institute in France for its work in predictive analytics and new oncology practices.AlphaFold: Mentioned by Gretchen as a research initiative like Google DeepMind, focusing on protein structures and potentially new treatments, including psychedelics for depression.PARP Inhibitors: Discussed in the context of drug approvals for various cancers and their use in clinical trials, specifically highlighted by Gretchen.Maya Zlatanova, CEO of TrialHub Gretchen Knoll, Président and CEO of Wyvern Quill Consulting Follow the show on LinkedIn to connect with guests and learn first about new episodes.